Drug Trial Radar · NCT07444489
A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE)
Last checked: Nov 20, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
201
Planned (sponsor's estimate)
Start
Apr 16, 2026
Primary completion
Dec 31, 2031
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and then developed antibody-mediated rejection (AMR) or microvascular inflammation (MVI). AMR happens when the body's immune system creates donor-specific antibodies (DSAs) that attack the transplanted kidney. In late AMR, this typically happens more than 6 months after the kidney transplant. MVI is a condition where the small blood vessels in the transplanted kidney become inflamed. MVI can happen with or without DSAs. Both AMR and MVI can cause the transplanted kidney to stop working properly. Two earlier studies looked at felzartamab in kidney transplant recipients. Study 299AR301 (TRANSCEND) (NCT06685757) included participants with AMR. Study 299AR201 (TRANSPIRE) (NCT07219043) included participants with MVI. This study, 299AR302-299AR301 LTE, is a long-term extension of both of these "parent" studies. Participants who join this study will have the opportunity to receive felzartamab for up to 4 more years after completing their parent study. The goal of this study is to learn more about the long-term safety and effects of felzartamab in people with kidney transplants. This study is part of a group of studies looking at long-term felzartamab use in people with organ transplants. This study is a substudy of the main study 299AR302. The main question researchers will answer relate to safety. Namely, how many participants have adverse events during the study and how lab test results change over time. Adverse events are health problems that may or may not be caused by the study drug. Researchers will perform kidney biopsies to track kidney health. Researchers will also study how felzartamab affects kidney inflammation, kidney function, immune activity, and overall health. The study will be done as follows: * Participants who complete the final visit of the treatment period in one of the parent studies can enroll in this study. This includes participants who stopped receiving felzartamab early but still attended their final visits. * Participants who did not stop receiving felzartamab in their parent study will continue to receive felzartamab for up to 4 more years in this study. Participants may also stop felzartamab during this study at any time. * Participants who stopped receiving felzartamab in their parent study will only attend study visits for health monitoring- they will not receive felzartamab. * Felzartamab will be given as an intravenous (IV) infusion, which is a slow injection into a vein using a needle. * Participants receiving felzartamab may have up to 27 study visits over 200 weeks with an additional safety follow-up visit after their final dose. * Participants who are not receiving felzartamab may have up to 9 study visits over 200 weeks.
Conditions
- Antibody-mediated Rejection
- Microvascular Inflammation
Interventions
FelzartamabDrug
Administered IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events of Special Interest (AESI)Time frame: From first dose of study drug up to end of study follow-up (Up to Week 204)
- Number of Participants who Discontinue Treatment due to an AETime frame: From first dose of study drug up to end of study follow-up (Up to Week 204)
- Number of Participants with Clinically Significant Laboratory, Vital Signs and Electrocardiograms (ECGs) AbnormalitiesTime frame: From first dose of study drug up to end of trial visit (up to Week 200)
Locations
15 sites in 2 countries. Site status is shown where the registry gives one.
Keck Medical Center of USC
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UCLA College of Medicine
Los Angeles, California
California Pacific Medical Center (Sutter Health)
San Francisco, California
Mayo Clinic
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Nebraska Medical Center (UNMC) - Nebraska Medicine - Nebraska Medical Center
Omaha, Nebraska
Cooperman Barnabas Medical Center
West Orange, New Jersey
Cleveland Clinic
Cleveland, Ohio
The Ohio State University
Columbus, Ohio
Penn Medicine - Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Virginia Commonwealth University
Richmond, Virginia
University of Washington Medical Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Providence Health Care - St. Paul's Hospital
Vancouver, British Columbia, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.